Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk: A 2-Sample Mendelian Randomization Study.

Tushar Sood^1,2, Nicolas Perrot^1,3,4, Michael Chong^1,3,4, Pedrum Mohammadi-Shemirani^1,3,4,5, Maha Mushtaha¹, Darryl Leong^1,6, Sumathy Rangarajan¹, Sibylle Hess⁷, Salim Yusuf^1,6, Hertzel C Gerstein^1,6, Guillaume Paré^1,3,4, Marie Pigeyre^1,6

¹Population Health Research Institute, Hamilton, Ontario, Canada.

²Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

³Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

⁴Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.

⁵Deep Genomics Inc, Toronto, Ontario, Canada.

⁶Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

⁷Global Medical Diabetes, Sanofi, Frankfurt, Germany.

PubMed PMC DOI PDF

Abstract

IMPORTANCE: Cardiometabolic parameters are established risk factors for COVID-19 severity. The identification of causal or protective biomarkers for COVID-19 severity may facilitate the development of novel therapies. OBJECTIVE: To identify protein biomarkers that promote or reduce COVID-19 severity and that mediate the association of cardiometabolic risk factors with COVID-19 severity. DESIGN,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.